-
BI 2536: A Practical PLK1 Inhibitor Workflow
2026-09-12
BI 2536 combines nanomolar PLK1 potency with a workflow that connects mitotic arrest, apoptosis, and checkpoint-complex biochemistry. This guide shows how to move from dose–response experiments to mechanistic p31comet assays and tumor xenograft model planning while avoiding common interpretation and solubility errors.
-
HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus
2026-09-11
The HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus supports in vitro transcription of randomly Cy3-modified RNA probes for applications such as in situ hybridization, Northern blotting, and fluorescence-based RNA analysis. It is intended for research use only and should not be used for diagnostic, therapeutic, clinical, or medical workflows.
-
Triacetin Workflows for Translational Research
2026-09-11
Triacetin supports distinct workflows in glioblastoma apoptosis studies, metabolic signaling, and ocular formulation screening. This guide shows how to separate its formulation role from its bioactivity, select defensible concentrations, and build controls that improve assay interpretation.
-
2',7'-Dichlorofluorescein diacetate ROS Workflow
2026-09-10
Build a practical intracellular ROS measurement workflow around 2',7'-Dichlorofluorescein diacetate for microscopy, flow cytometry, and plate-based assays. The approach connects redox readouts with a pH/ROS-responsive pancreatic cancer nanocarrier study while emphasizing controls, normalization, and the probe’s limits as a general rather than selective oxidative-stress indicator.
-
Ferrostatin-1 in Ferroptosis Assay Workflows
2026-09-10
Ferrostatin-1 (Fer-1) provides a practical pharmacological rescue control for distinguishing ferroptosis from nonspecific cytotoxicity. This guide translates a rheumatoid arthritis fibroblast-like synoviocyte study into reproducible workflows for lipid ROS, viability, inflammatory signaling, and pathway-validation experiments.
-
SmD2 Acetylation, Splicing, and PARP Inhibitor Sensitivity
2026-09-09
This study identifies SmD2 as a mechanistic link between spliceosome regulation, BRCA1/FANC cassette-exon processing, and PARP inhibitor sensitivity in hepatocellular carcinoma. Its findings support an acetylation-centered strategy in which HDAC2 inhibition and PARP blockade may improve responses in preclinical HCC models.
-
Betaine Hydrochloride for Enzyme Assays
2026-09-09
Betaine hydrochloride supports controlled, water-based screening in metabolic enzyme research, protease assays, cell culture, and molecular biology workflows. This guide separates evidence from the oridonin cancer literature and shows how to use the compound as a defined matrix variable rather than assuming it is an anticancer treatment.
-
Gemcitabine Workflows for DNA Damage Research
2026-09-08
Build reproducible Gemcitabine experiments around replication stress, checkpoint activation, and apoptosis rather than relying on a single viability endpoint. This guide also extends the workflow into cholangiocarcinoma metabolism and macrophage co-culture models while clearly separating established evidence from exploratory assay design.
-
AT13387: Hsp90 Inhibitor Workflows for Cancer Research
2026-09-08
AT13387 combines high-affinity Hsp90 engagement with a practical workflow for studying client-protein loss, cell cycle arrest, and apoptosis induction. This guide also shows how to separate Hsp90-driven cancer phenotypes from membrane-rupture and secretion signals highlighted by recent norovirus research.
-
CDC42 Polarity Controls Intestinal Stem Cell Fate
2026-09-07
The reference study shows that CDC42-dependent apical-basal polarity is an upstream regulator of the intestinal stem cell to transit-amplifying cell transition. Its genetic and pharmacological experiments identify a YAP/TAZ–Ereg–EGFR–mTOR cascade that links epithelial architecture to crypt proliferation independently of canonical Wnt signaling.
-
RapaLink-1: Third-Generation mTOR Inhibitor
2026-09-05
RapaLink-1 combines resistance-aware mTOR kinase inhibition with a practical framework for cancer and embryonic dormancy research. Its strongest value is experimental flexibility: researchers can separate pathway suppression, glioma cell growth inhibition, and reversible dormancy-like phenotypes instead of treating them as interchangeable endpoints.
-
Anlotinib Hydrochloride: Angiogenesis Mechanisms
2026-09-05
The reference study shows that anlotinib suppresses angiogenesis by jointly inhibiting VEGFR2, PDGFRβ, and FGFR1 activation and their shared ERK signaling output. Its use of endothelial migration, tube formation, rat aortic ring, and chicken CAM models provides a coherent preclinical framework for evaluating multi-target angiogenesis inhibition in cancer research.
-
Baicalin Methyl Ester and Intestinal Barrier Repair
2026-09-04
A 2024 Biomedicine & Pharmacotherapy study examined baicalin methyl ester in LPS-challenged mice and MODE-K intestinal epithelial cells. The work connects inflammatory signaling, MLCK activity, and tight-junction remodeling through the P65/TNF-α/MLCK/ZO-1 axis, providing a mechanistic framework for LPS-induced intestinal barrier damage research.
-
Removing Pollen Interference in Bioaerosol EEM
2026-09-04
Zhang and colleagues developed a fluorescence-data workflow that reduces pollen interference when classifying hazardous bioaerosol components. By combining excitation–emission matrix preprocessing, fast Fourier transform features, and random forest classification, the study reported a 9.2-percentage-point improvement and 89.24% accuracy across 31 sample types.
-
Bacitracin (B1670): Practical Research Guide
2026-09-03
Bacitracin (B1670) is a quality-controlled peptide antibiotic for controlled antibacterial research involving bacterial growth, cell-wall processes, and peptidoglycan synthesis. It is intended for scientific research workflows only and should not be used for diagnostic, clinical, or medical applications.